Can Mounjaro and Zepbound help with weight loss in people with long-term obesity, and who is eligible in Europe?

Mounjaro and Zepbound explained: tirzepatide, GLP-1/GIP receptor agonist therapy, chronic obesity management, BMI criteria, and prescribing standards.

In this episode, we review clinical evidence on tirzepatide for long-term obesity and how doctors assess eligibility under EU medical guidance.

You’ll learn:

• What tirzepatide is and how dual GLP-1/GIP receptor agonists work

• Approved BMI thresholds (≥30, or ≥27 with weight-related conditions)

• Evidence from clinical trials on average weight reduction

• The role of lifestyle intervention alongside medication

• Common side effects: nausea, diarrhoea, constipation

• Monitoring requirements: HbA1c, kidney f ...